Ketoconazole 2% shampoo in the treatment of tinea versicolor: A multicenter, randomized, double-blind, placebo-controlled trial

被引:27
|
作者
Lange, DS
Richards, HM
Guarnieri, J
Humeniuk, JM
Savin, RC
Reyes, BA
Hickman, J
Pariser, DM
Pariser, RJ
Sherertz, EF
Grossman, RM
Gisoldi, EM
Klausner, MA
机构
[1] Janssen Pharmaceut, Dept Med Affairs, Titusville, NJ 08560 USA
[2] Upstate Clin Res, Greer, SC USA
[3] Savin Dermatol Ctr, New Haven, CT USA
[4] Int Dermatol Res, Miami, FL USA
[5] Educ & Res Fdn, Lynchburg, VA USA
[6] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[7] Virginia Clin Res, Norfolk, VA USA
[8] Wake Forest Univ, Bowman Gray Sch Med, Dermatol Clin Studies Ctr, Winston Salem, NC USA
[9] Johnson & Johnson Consumer Prod Inc, Skillman, NJ 08558 USA
关键词
D O I
10.1016/S0190-9622(98)70267-1
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Tinea versicolor is a common superficial fungal infection caused by a lipophilic yeast. This chronically recurring opportunistic infection is especially prevalent in tropical and semitropical regions. The topical short-term application of ketoconazole 2% shampoo may provide effective and safe therapy for tinea versicolor. Objective: The purpose of this study was to evaluate the efficacy and safety of a single application (1 day) versus three daily applications (3 days) of ketoconazole 2% shampoo versus placebo shampoo in the treatment of mycologically confirmed tinea versicolor. Methods: Three hundred twelve patients were included in the primary analyses for this 31-day study. Global evaluation scores were measured on days 10 and 31 with a 5-point scale (1 = healed to 5 = worsening), and a cellophane tape test was done at baseline and days 3, 10, and 31. Efficacy was assessed by clinical response, defined as both a global evaluation score of 1 (healed) and a negative cellophane tape test on day 31. Signs and symptoms of tinea versicolor (scaling, itching, erythema, hypopigmentation, hyperpigmentation) also were evaluated at baseline, day 10, and day 31 with a 4-point scale (0 = absent to 3 = severe). Results: Both regimens of ketoconazole shampoo were significantly (P <.001) more effective than placebo for rate of clinical response, global evaluation scores, and mycologic outcomes (cellophane tape test). The clinical response rates at day 31 were 73%, 69%, and 5% for the 3-day ketoconazole, 1-day ketoconazole, and placebo groups, respectively. The difference in the efficacy of the two ketoconazole treatment regimens was not statistically significant. There were no significant differences between any of the treatment groups in the number of patients who experienced adverse events. No serious adverse events occurred and no patient withdrew from the trial prematurely because of an adverse event. Conclusion: Ketoconazole 2% shampoo, used as a single application or daily for 3 days, is safe and highly effective in the treatment of tinea versicolor.
引用
收藏
页码:944 / 950
页数:7
相关论文
共 50 条
  • [41] Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial
    Levin, Frances R.
    Mariani, John J.
    Brooks, Daniel J.
    Pavlicova, Martina
    Cheng, Wendy
    Nunes, Edward V.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2011, 116 (1-3) : 142 - 150
  • [42] A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
    Miller, I.
    Lynggaard, C. D.
    Lophaven, S.
    Zachariae, C.
    Dufour, D. N.
    Jemec, G. B. E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (02) : 391 - 398
  • [43] Levetiracetam as an Adjunctive Treatment for Mania: A Double-Blind, Randomized, Placebo-Controlled Trial
    Keshavarzi, Amir
    Sharifi, Aziz
    Jahangard, Leila
    Soltanian, Alireza
    Bruehl, Annette Beatrix
    Ahmadpanah, Mohammad
    Brand, Serge
    [J]. NEUROPSYCHOBIOLOGY, 2022, 81 (03) : 192 - 203
  • [44] Metoclopramide for the treatment of Tourette syndrome: A randomized, double-blind, placebo-controlled trial
    Nicolson, R
    Smith, J
    Castellanos, FX
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S277 - S277
  • [45] Treatment of snorers with a volatile oil -: A randomized, double-blind placebo-controlled trial
    Ulfberg, J
    Nyström, B
    [J]. ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 2001, 63 (05): : 298 - 301
  • [46] Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence
    Heinzerling, Keith G.
    Swanson, Aimee-Noelle
    Kim, Soeun
    Cederblom, Lisa
    Moe, Ardis
    Ling, Walter
    Shoptaw, Steven
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2010, 109 (1-3) : 20 - 29
  • [47] SERLOPITANT FOR TREATMENT OF CHRONIC PRURITUS: RESULTS OF A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL
    Yosipovitch, Gil
    Stander, Sonja
    Kerby, Matthew B.
    Larrick, James W.
    Perlman, Andrew J.
    Schnipper, Edward F.
    Zhang, Xiaoming
    Tang, Jean Y.
    Luger, Thomas A.
    Steinhoff, Martin
    [J]. ACTA DERMATO-VENEREOLOGICA, 2017, 97 (08) : 1015 - 1015
  • [48] Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial
    Coffin, Phillip Oliver
    Santos, Glenn-Milo
    Das, Moupali
    Santos, Deirdre M.
    Huffaker, Shannon
    Matheson, Tim
    Gasper, James
    Vittinghoff, Eric
    Colfax, Grant N.
    [J]. ADDICTION, 2013, 108 (04) : 751 - 761
  • [49] A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis
    Wallwork, B
    Coman, W
    Mackay-Sim, A
    Greiff, L
    Cervin, A
    [J]. LARYNGOSCOPE, 2006, 116 (02): : 189 - 193
  • [50] Randomized, double-blind, placebo-controlled trial of rofecoxib for the acute treatment of migraine
    Tepper, S
    Silberstein, S
    Brandes, J
    Venkatraman, S
    Vrijens, F
    Malbecq, W
    Visser, WH
    Reines, S
    Yuen, E
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 300 - 300